However, following targeting of the 72 resistance genes we observed that only a very limited subset targeted for silencing were capable of preserving signalling through the PI3K, MAPK, and mTOR pathways, all known mediators of resistance in EGFR mutant lung cancer (Fig. 2b–d, Supplementary Data 8–10). The gene discussed is EGFR; the disease is lung carcinoma.